Inventiva : Company presentation - Jefferies Virtual Healthcare Conference

DISCLAIMER

This document has been prepared by Inventiva (the "Company") solely for the purpose of this presentation. This document is not to be reproduced by any person nor is it to be distributed.This presentation includes only summary information and does not purport to be comprehensive. Any information in this presentation, whether from internal or from external sources, is purely indicative and has no contractual value. The information contained in this presentation are provided as at the date of this presentation. Certain information included in this presentation and other statements or materials published or to be published by the Company are not historical facts but are forward-looking statements. The forward-looking statements are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and market in which the Company operates, and involve known and unknown risk, uncertainties and other factors, which may cause actual results, performance or achievements, or industry results or other events, to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include those discussed or identified under Chapter "Risk factors" in the Company's registration document (document de reference) filed with the French Financial markets authority (AMF -Autorité des marchés financiers), available on the Company's website (www.inventivapharma.com) and on the website of the AMF. The

Company may not actually achieve the plans, intents or expectations disclosed in its forward-looking statements and you should not place undue reliance on the forward-looking statements contained herein. There can be no assurance that the actual results of the Company's development activities and results of operations will not differ materially from the Company's expectations.

Factors that could cause actual results to differ from expectations include, among others, the Company's ability to develop safe and effective products, to achieve positive results in clinical trials, to obtain marketing approval and market acceptance for its products, and to enter into and maintain collaborations; as well as the impact of competition and technological change; existing and future regulations affecting the Company's business; and the future scope of the Company's patent coverage or that of third parties.

The information contained in this presentation has not been subject to independent verification. No representation or warranty, express or implied, is made by the Company or any of its affiliates, advisors, representatives, agents or employees as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company, nor any of its respective affiliates, advisors, representatives, agents or employees, shall bear any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. Such information is subject to modification at any time, including without limitation as a result of regulatory changes or changes with respect to market conditions, and neither the Company, nor any of its affiliates, advisors, representatives, agents or employees, shall, nor has any duty to, update you.

Inventiva: highlights

Clinical stage biotech with focus onoral small molecules for high unmet needin fibrosis, lysosomal storage disorders and oncology

Two unencumbered late stage assetsin two high value indications-Lanifibranor- only pan-PPAR agonist in clinical development for NASH, Phase IIb data due in June-Odiparcil- first orally available therapy for MPS

A clinical stage partnership with AbbVie

• -ABBV-157 RORprogramwith potential in several auto-immune indications currently in clinical development in patients with psoriasis

• -Inventiva eligible to milestone payments and sales royalties

Compelling early stage pipeline-YAP-TEAD program in late pre-clinical stage approaching clinical candidate selection

State of the art R&D capabilitiesincluding wholly owned 'pharma scale' discovery facilities with adiscovery enginefocused on nuclear receptors, transcription factors and epigenetic targets-240,000 compound library, 60% of which are proprietary

Strong US and European shareholder base and experienced senior managementteam with a track record of operational and scientific excellence

Cash position allowing arunway until end of Q3 2021

Lanifibranor: theonly pan-PPAR agonist in clinical development for the treatment of NASH

Moderate and balanced pan-PPAR agonist activity(PPAR, PPARand PPAR) with differentiated chemical structure

Once daily oral administration

Efficacy demonstratedon insulin-sensitivity, dyslipidemia, steatosis, ballooning, inflammation, hepatic fibrosis and cirrhosis in preclinical models

Phase IIa(1)trial demonstrated pan-PPAR agonist activity,supporting dose selection for NASH clinical trial

Favorable safety profiledemonstrated in:

• 24-months rodent and 12-month monkey studies leading toPPAR class clinical hold liftedby FDA

• Phase I trials with more than200healthy volunteers(2)and Phase IIa study with47TD2M patients

• Approximately250patients have been treated for 24 or 48 weeks in our ongoing and completed Phase IIb clinical trials

• In connection with these trials, lanifibranor has undergone a total of7 positive DSMB reviews

Composition of matter patent delivered in 59 countries and method of use patent granted in the US,

China and in the EU:limit of exclusivity 2035

FAST Trackdesignation granted by FDA

(1) Conducted by Abbott prior to our funding; (2) Including 125 healthy volunteers in the phase I conducted by Abbott prior to our funding

PPARefficacy is well established in NASH

PPARactivation by pioglitazone improves steatosis, ballooning, inflammation and metabolic markers in NASH patients after 6 months or 18 months of treatment

Pioglitazone (PPAR)

Belfort NASH study 6 month treatmentCusi NASH study 18 month treatment

Placebo	Pio	P	Placebo	Pio	P
Steatosis (% patients improved)	38%	65%	0.001	26%	71%	< 0.001
Inflammation (% patients improved)	29%	65%	0.001	22%	49%	= 0,004
Ballooning (% patients improved)	24%	54%	0.001	24%	51%	= 0,004
NASH resolution (% patients)	-	NA	-	19%	51%	< 0.001
Fibrosis (mean change in score)	-	NS	-	0	- 0.5	= 0.039

Pioglitazone improves advanced fibrosis

Pioglitazone improves advanced fibrosis(stage F3-F4) as indicated by an increase in the number of NASH patients whose fibrosis stage changed from F3-F4 to F0-F2 at the end of treatment

Source: Corey KE and Malhi H, Hepatology 2016. Note: clinical trial not conducted by InventivaCorporate Presentation | 2020